---
title: Registry of Patients With Plasma Cell Disorders
nct_id: NCT06286215
overall_status: NOT_YET_RECRUITING
sponsor: Siriraj Hospital
study_type: OBSERVATIONAL
primary_condition: Plasma Cell Disorders
canonical_url: "https://parkinsonspathways.com/agent/trials/NCT06286215.md"
clinicaltrials_gov: "https://clinicaltrials.gov/study/NCT06286215"
ct_last_update_post_date: 2024-02-29
last_seen_at: "2026-05-12T07:34:38.685Z"
source: ClinicalTrials.gov (mirrored, no enrichment)
---
# Registry of Patients With Plasma Cell Disorders

**NCT ID:** [NCT06286215](https://clinicaltrials.gov/study/NCT06286215)

## Key Facts

- **Status:** NOT_YET_RECRUITING
- **Study Type:** OBSERVATIONAL
- **Target Enrollment:** 750
- **Lead Sponsor:** Siriraj Hospital
- **Conditions:** Plasma Cell Disorders
- **Start Date:** 2024-04-01
- **Completion Date:** 2035-04-01
- **CT.gov Last Update:** 2024-02-29

## Brief Summary

The goal of this observational study is to register patients with plasma cell disorders. The main questions it aims to answer are:

* The incidence of plasma cell disorders both before and after malignancy
* Time to progression of monoclonal gammopathy of undetermined significant (MGUS) or smoldering multiple myeloma (SMM) to light chain amyloidosis or multiple myeloma (MM)
* Progression free survival (PFS)
* overall survival
* factors influencing overall survival, progression-free survival, and time to progression
* Symptoms and signs of the disease during the diagnosis and relapse phases, including the causes of mortality in plasma cell disorder patients.
* genetic characteristics of plasma cell disorder
* cost-effectiveness of treatment in Thailand Participants will be collected the data of baseline diagnosis, treatment, treatment results of all admission and follow-up visits from hospital medical record.

## Eligibility

- **Minimum age:** 18 Years
- **Sex:** ALL
- **Healthy Volunteers:** No

```
Inclusion Criteria:

* Both existing and newly diagnosed patients with plasma cell disorders, including monoclonal gammopathy of undetermined significance, smoldering multiple myeloma, POEMS, light chain amyloidosis, solitary plasmacytoma, and multiple myeloma, according to the diagnostic criteria of the International Myeloma Working Group 2014
* Aged 18 years and above

Exclusion Criteria:

* insufficient data needed for analysis
```

## Primary Outcomes

- **register the plasma cell disorder patients** _(time frame: 10 years)_ — register the plasma cell disorder patients

## Secondary Outcomes

- **incidence of plasma cell disorders** _(time frame: 10 years)_
- **Time to progression** _(time frame: 10 years)_
- **Progression free survival** _(time frame: 10 years)_
- **overall survival** _(time frame: 10 years)_
- **influencing factors** _(time frame: 10 years)_
- **Symptoms and signs** _(time frame: 10 years)_
- **genetic characteristics** _(time frame: 10 years)_
- **cost-effectiveness** _(time frame: 10 years)_

## Recent Field Changes (last 30 days)

- `status.overallStatus` — added _(2026-05-12)_
- `status.primaryCompletionDate` — added _(2026-05-12)_
- `status.completionDate` — added _(2026-05-12)_
- `status.lastUpdatePostDate` — added _(2026-05-12)_
- `design.enrollmentCount` — added _(2026-05-12)_
- `eligibility.criteria` — added _(2026-05-12)_
- `eligibility.minAge` — added _(2026-05-12)_
- `eligibility.sex` — added _(2026-05-12)_
- `outcomes.primary` — added _(2026-05-12)_
- `outcomes.secondary` — added _(2026-05-12)_
- `sponsor.lead` — added _(2026-05-12)_
- `results.hasResults` — added _(2026-05-12)_

---

*Canonical: https://parkinsonspathways.com/agent/trials/NCT06286215.md*  
*Source data (authoritative): https://clinicaltrials.gov/study/NCT06286215*  
*This page is a raw mirror with no AI summary, no editorial enrichment, and no Parkinson's-specific filtering.*